Business · 28/10/2019Updated: 10/17/2026 · 1 min read
InvaGen Pharmaceuticals, Inc. Faces FDA Proposal to Withdraw Trandolapril Tablets Approval
Summary
The FDA is proposing to withdraw approval of an abbreviated new drug application for trandolapril tablets due to repeated failures in submitting required data to support bioequivalence, and is offering the ANDA holder the chance to request a hearing on the proposal.